A Forward Look, The Year Ahead - Research Report on PepsiCo, Inc., The Coca-Cola Company, Covidien plc, Medtronic, Inc. and

    A Forward Look, The Year Ahead - Research Report on PepsiCo, Inc., The
  Coca-Cola Company, Covidien plc, Medtronic, Inc. and Monster Beverage Corp

PR Newswire

NEW YORK, March 15, 2013

NEW YORK, March 15, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting PepsiCo,
Inc. (NYSE:PEP), The Coca-Cola Company (NYSE:KO), Covidien plc (NYSE: COV),
Medtronic, Inc. (NYSE: MDT) and Monster Beverage Corp (NASDAQ:MNST). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

PepsiCo, Inc. Research Report

Beating market estimates for the past year, Pepsi reported a 17% increase in
the fourth quarter earnings of $1.66 billion or $1.06 per share, up from the
same year-ago quarter earnings of $1.42 billion or 89 cents per share. The
company also reported an organic revenue growth of 5% for the same quarter and
the full year. With this strong quarter result, Pepsi has announced a new
buyback plan of as much as $10 billion in stock to return cash to investors.
This new repurchase program will begin in July 1, 2013 and will continue until
June 30, 2013. Furthermore, Pepsi also reported an increase of 5.6% in the
company's annualized dividend for the June 2013 payment, resulting from $2.15
to a price of $2.27 per share. Pepsi Chairman and CEO Indra Nooyi said that
the revenue growth reflects the company's "enviable portfolio of iconic
brands." Nooyi further noted that the company would continue maintaining its
hold in the global market. "Our recent brand-building initiatives and
innovation across the portfolio, including Quaker Real Medleys, Gatorade
Energy Chews, Pepsi Next and Doritos Locos Tacos, are translating into success
in the marketplace... We're encouraged by the progress we're making and expect
performance in the coming year to be consistent with our long-term targets."
The Full Research Report on PepsiCo, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.Investors-Alliance.com/r/full_research_report/e4cd_PEP]

--

The Coca-Cola Company Research Report

Meanwhile, Coca Cola's fourth quarter net income was a reported 14% increase
or $1.87 billion or 41 cents per share, up from the $1.66 billion of 36 cents
per share last year. Despite not meeting the estimates, Coca-Cola projected a
strong full-year global volume growth of 4%, while the full-year reported net
revenue growth is 3%. The company also posted remarkable growths in its
various global markets such as Thailand (+22%), India (+16%) and Russia (+8%)
for the full year. Coke Chairman and Chief Executive Officer Muhtar Kent said,
"We are pleased with our results we announced today. In a year marked by
continued uncertainty in the global economy, we delivered solid volume,
revenue and profit growth, and we realized further volume and value share
gains in nonalcoholic ready-to-drink beverages." For the coming year, Kent
recognizes the necessity of adapting to the shifts in the global economy. "We
must continue investing in our business so that we get even better -better at
collaborating, at innovating, at listening to consumers, customers and our
bottling partners and most importantly, at executing with precision. All of us
at Coca-Cola remain diligent about our results as we manage our business for
continued sustainable long-term success," he added. The Full Research Report
on The Coca-Cola Company - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/ed8f_KO]

--

Covidien plc Research Report

Irish healthcare company Covidien PLC recently reported first quarter net
sales of $3.06 billion, with a 5% growth compared to the same year-ago quarter
net sales. Adjusted diluted earnings amounted to $1.10 per share. In the same
vein, the Medical Devices segment of the company posted a remarkable sales
growth of 8%. "We're off to a very good start in fiscal 2013, with
first-quarter results exceeding our expectations," said Covidien Chairman,
President and CEO José E. Almeida. The Market Devices unit of the company is
expected to perform well and generate "above-market growth." The company has
recently received the FDA approval for its generic CONCERTA® extended-release
(ER) tablets, a prescription medication to stimulate the central nervous
system. Covidien has also released the results of its studies validating the
efficacy of its Solitaire™ FR Thrombectomy for Acute Revascularization (STAR)
device. Solitaire FR is designed to aid patients of acute ischemic stroke by
restoring blood flow and removing blood clots from the vessels. With over 800,
000 patients affected by acute ischemic stroke every year, Covidien aims to
attend to the need of a solution for this widespread public health issue. "We
remain confident that our robust pipeline of new products, sizable expansion
opportunities in emerging markets and recent promising portfolio additions
will enable us to meet the significant challenges of the global marketplace
and to continue to deliver good operational growth," Almeida said at the
conclusion of the quarterly report. The Full Research Report on Covidien plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/447a_COV]

--

Medtronic, Inc. Research Report

US medical technology company Medtronic Inc. posted a 4% revenue growth to $4
billion or 93 cents per share. International sales accounted for 46% of the
company's revenue during the said quarter, for a total of $1.856 billion. Omar
Ishrak, Medtronic Chairman and CEO also conveyed positive outlook brought
about by the company's strong open for 2013 and the latest financial quarter.
The company last week reported the result of a clinical study by The New
England Journal of Medicine on the benefits of Medtronic's deep brain
simulation therapy for Parkinson's disease patients. With an estimated 60,000
American diagnosed with Parkinson's disease every year, Covidien says that the
study's result gives way to an expansion of beneficial medical management
available for patients, as exemplified through the deep brain simulation.
Medtronic also received the FDA clearance for its AIRvance™ Bone Screw System
that is designed to allow surgeons to perform hyoid suspension procedure in
treating obstructive sleep apnea. Through aggressive research and development
outputs such as AIRvance, Medtronic is among the leaders in "transforming
global healthcare by implementing our long-term strategies of economic value
and globalization." Ishrak further said that the company remains "committed to
delivering dependable growth in a changing healthcare environment as reflected
in our third quarter performance. Several businesses and regions contributed
to our steady growth this quarter, and we are focused on effectively managing
headwinds and tailwinds to deliver balanced and consistent overall
performance." The Full Research Medtronic, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/b91b_MDT]

--

Monster Beverage Corp Research Report

As the maker of the Monster Energy®, one of the questioned energy drinks
products, Monster released a statement contesting the agency report and
calling it "highly misleading." The company explained that the DAWN report
contains little to no information about the association between the hospital
emergencies reported and the consumption of energy drinks. Monster also noted
that Monster Energy drinks contain even less caffeine than regular
coffeehouse-brewed coffee and that about 8 billion cans of the energy drinks
have been sold and "safely consumed" in the U.S. and around the world.
Currently having a bullish impression in the community, Monster is set out to
roll more new products this year, along with expansion in the Asian and
Central American market. Addressing its adrenaline-pumped market, Monster
continuously implements its brand recognition formula by sponsoring extreme
sports events, rock concerts and tours, and affiliations with athletes and
personalities. The Full Research Report on Monster Beverage Corp - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/31c1_MNST]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(480)-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.